000			01786 a2200505 4500
005			20250513042927.0
264		0	_c19950630
008			199506s 0 0 eng d
022			_a0009-9236
024	7		_a10.1016/0009-9236(95)90034-9 _2doi
040			_aNLM _beng _cNLM
100	1		_aThompson, D S
245	0	0	_aA phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. _h[electronic resource]
260			_bClinical pharmacology and therapeutics _cMay 1995
300			_a499-507 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aChromatography, High Pressure Liquid
650	0	4	_aCohort Studies
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aEtoposide _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHalf-Life
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aLeukopenia _xchemically induced
650	0	4	_aMale
650	0	4	_aMetabolic Clearance Rate
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aOrganophosphorus Compounds _xadministration & dosage
700	1		_aGreco, A
700	1		_aMiller, A A
700	1		_aSrinivas, N R
700	1		_aIgwenezue, K B
700	1		_aHainsworth, J D
700	1		_aSchacter, L P
700	1		_aKaul, S
700	1		_aBarbhaiya, R H
700	1		_aGarrow, C
773	0		_tClinical pharmacology and therapeutics _gvol. 57 _gno. 5 _gp. 499-507
856	4	0	_uhttps://doi.org/10.1016/0009-9236(95)90034-9 _zAvailable from publisher's website
999			_c7767440 _d7767440